| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Pharmacology, Division of Cancer Treatment [P. M. O'C., K. W., M. S., V. A. B., K. W. K.], and Lymphoma Section, Pediatric Oncology Branch [I. M.], National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
We surveyed 11 Burkitt's lymphoma cell lines for chemosensitivity to nitrogen mustard (HN2) in order to determine whether any simple correlates to cytotoxic response might be revealed. The lines tested varied over a 5-fold range in concentration of HN2 required to inhibit tumor cell growth by 50%. Drug sensitivity correlated neither with continental origin of tumor, growth fraction, presence of Epstein-Barr virus, nor with the precise locations of (8;14) translocation breakpoints. Furthermore, contrary to experience with other cell lines, no simple correlation was found between the HN2 sensitivity of the four most divergent lines (low sensitivity, CA46 and MC116 cells; high sensitivity, Namalwa and JLP119 cells) and exposure to DNA cross-links (area under the DNA cross-linking-versus-time curve). In addition, we found similar extents of gene-specific HN2-induced damage in the native and translocated c-myc alleles of CA46 and JLP119 cells. At equimolar HN2 treatment, CA46 cells exhibited a profound arrest in G2M phase, while JLP119 cells exhibited prolonged S-phase delay. This suggested that despite similar DNA cross-link exposure, JLP119 cells were less able to complete DNA replication while repair was in progress. As cell cycle distribution returned to near normal, JLP119 cells exhibited DNA degradation characterized by oligonucleosome-sized DNA fragments prior to cell membrane disintegration. Our findings indicate that HN2-sensitive Burkitt's lymphomas cells may be more susceptible to delay in S phase for a given frequency of DNA cross-links and that prolongation of S phase correlated with apoptotic cell death.
1 To whom requests for reprints should be addressed, at Laboratory of Molecular Pharmacology, Division of Cancer Treatment, National Cancer Institute, Building 37, Room 5C25, Bethesda, MD 20892.
2 Present address: Department of Biology and Toxicology, National Institutes of Occupational Health, Lerso-Parkalle 105, DK 2100, Copenhagen, Denmark.
Received 7/15/91. Accepted 10/ 2/91.
This article has been cited by other articles:
![]() |
D. C. Malins, K. M. Anderson, N. K. Gilman, V. M. Green, E. A. Barker, and K. E. Hellstrom From The Cover: Development of a cancer DNA phenotype prior to tumor formation PNAS, July 20, 2004; 101(29): 10721 - 10725. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sunters, D. P. Thomas, W. A. Yeudall, and A. E. Grigoriadis Accelerated Cell Cycle Progression in Osteoblasts Overexpressing the c-fos Proto-oncogene: INDUCTION OF CYCLIN A AND ENHANCED CDK2 ACTIVITY J. Biol. Chem., March 12, 2004; 279(11): 9882 - 9891. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Berardini, P. L. Foster, and E. L. Loechler DNA Polymerase II (polB) Is Involved in a New DNA Repair Pathway for DNA Interstrand Cross-Links in Escherichia coli J. Bacteriol., May 1, 1999; 181(9): 2878 - 2882. [Abstract] [Full Text] |
||||
![]() |
H. W. Findley, L. Gu, A. M. Yeager, and M. Zhou Expression and Regulation of Bcl-2, Bcl-xl, and Bax Correlate With p53 Status and Sensitivity to Apoptosis in Childhood Acute Lymphoblastic Leukemia Blood, April 15, 1997; 89(8): 2986 - 2993. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |